The Biopharma Pod podcast

Immunocore CEO: 3rd Big Pharma Eying Unique Cancer Targeting Tech

0:00
5:10
Reculer de 15 secondes
Avancer de 15 secondes
Immunocore is looking for more licensees for its cancer targeting technology following recent discovery and development deals with GSK and Genentech.

D'autres épisodes de "The Biopharma Pod"